Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment

NCT03538522 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.

NCT NCT03538522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03538522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment
Lead sponsor
Biomed Industries, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2018
Completion date
October 30, 2019
Enrollment
126 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia, alzheimer disease, cognitive disorder, cognitive impairment, dementia with lewy bodies, dementia, vascular, mild cognitive impairment, neurocognitive disorders, neurodegenerative diseases, tauopathies